Q4 2025 Intellia Therapeutics Inc Earnings Call Transcript
Key Points
- Intellia Therapeutics Inc (NTLA) achieved rapid enrollment in their Phase 3 clinical trials for both lonvo-z and Nex-z, with the HAELO trial completing enrollment ahead of schedule.
- The FDA lifted the clinical hold on the MAGNITUDE-2 trial, allowing Intellia to resume patient screening and enrollment.
- Lonvo-z has shown promising results, with 76% of patients attack-free for at least 12 months in Phase 1 and 2 trials, indicating a strong potential for long-term efficacy.
- Intellia's financial position remains strong, with $605.1 million in cash and equivalents, expected to fund operations into the second half of 2027.
- The company has made significant progress in commercial readiness for lonvo-z, including scaling their field medical team and engaging with payers and patient advocacy groups.
- The MAGNITUDE trial for Nex-z was placed on clinical hold due to elevated liver transaminases and total bilirubin observed in a patient, delaying progress.
- Intellia had to implement additional liver laboratory tests and modify screening criteria to address safety concerns, which may impact trial timelines.
- The company reported a net loss of $95.8 million for the fourth quarter of 2025, although this was an improvement from the previous year.
- There is uncertainty regarding the long-term safety of Nex-z, as the mechanism of liver injury is believed to be immune-mediated, requiring careful monitoring.
- Intellia faces competition in the HAE market from existing therapies and emerging RNA silencing technologies, which may impact market penetration.
Hello, and welcome to Intellia Therapeutics' fourth quarter and full year 2025 conference call. My name is Drew, and I will be your conference operator today. Please be advised that today's call is being recorded. I will now turn the call over to Jason Fredette, Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.
Thank you, operator. Hello, everyone. Earlier this morning, we issued a press release outlining recent business updates in our fourth quarter and full year financial results. This document can be found on the Investors and Media section of Intellia's website at intelliatx.com. At this time, I would like to take a minute to remind listeners that during this call, Intellia management may make certain forward-looking statements. We ask that you refer to our SEC filings available at sec.gov for a discussion of potential risks and uncertainties. All information presented on this call is current as of today.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
